PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10645030-3 1999 OBJECTIVES: The aim of the study was to investigate the influence of erythropoietin treatment during long-term 15 months study on serum vitamin A levels and its protein carriers, prealbumin and retinol-binding protein, on erythrocyte vitamin B1, B2 and B6 and folic acid and on serum or plasma vitamins B12, C and E levels in hemodialyzed patients. Folic Acid 260-270 erythropoietin Homo sapiens 69-83 11452966-0 2001 Folate and vitamin B12 supplementation in very low birth weight infants treated with erythropoietin: a cautionary note. Folic Acid 0-6 erythropoietin Homo sapiens 85-99 11759218-22 2001 Folic acid (10 mg/day) enhances response to EPO. Folic Acid 0-10 erythropoietin Homo sapiens 44-47 11590253-8 2001 Deficiencies in vitamin B(12), folic acid and potentially vitamin C can all reduce the efficacy of treatment with rh-Epo. Folic Acid 31-41 erythropoietin Homo sapiens 117-120 10661482-1 2000 AIMS: To examine the possible relationships between recombinant human erythropoietin (rhEPO) therapy, serum folic acid and homocysteine levels in a cohort of stable, chronically hemodialyzed patients. Folic Acid 108-118 erythropoietin Homo sapiens 70-84 10661482-11 2000 Significant correlations (ANOVA) were observed between serum erythropoietin and folic acid levels (r = -0.382; p = 0.049), and between folic acid and homocysteine levels (r = -0.560; p = 0.002). Folic Acid 80-90 erythropoietin Homo sapiens 61-75 10851861-3 2000 In the present study we investigated whether the administration of recombinant human erythropoietin (rHuEpo) recombinant human erythropoietin in combination with iron and folic acid may ameliorate blood indices as an alternative choice to blood transfusion. Folic Acid 171-181 erythropoietin Homo sapiens 85-99 10645030-12 1999 Erythrocyte vitamin B6 and folic acid significantly decreased due to erythropoietin treatment. Folic Acid 27-37 erythropoietin Homo sapiens 69-83 10645030-14 1999 CONCLUSIONS: Supplementations of pyridoxine in the dose of 20 mg/day and of folic acid 5 mg/week in hemodialyzed patients during erythropoietin treatment are necessary. Folic Acid 76-86 erythropoietin Homo sapiens 129-143 10334668-12 1999 Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for patients with hyperhomocysteinaemia. Folic Acid 74-84 erythropoietin Homo sapiens 95-102 10334668-11 1999 Folic acid is supplemented routinely in haemodialysis patients, though evidence that it increases the efficacy of epoetin is limited. Folic Acid 0-10 erythropoietin Homo sapiens 114-121 10575307-0 1999 Correction of epoetin-resistant megaloblastic anaemia following vitamin B(12) and folate administration. Folic Acid 82-88 erythropoietin Homo sapiens 14-21 10050095-0 1999 Erythropoietin response to folic acid substitution. Folic Acid 27-37 erythropoietin Homo sapiens 0-14 8587618-0 1995 Folic acid supplementation improves erythropoietin response. Folic Acid 0-10 erythropoietin Homo sapiens 36-50 9159297-1 1997 The treatment efficacy of erythropoietin (EPO) in end-stage renal disease (ESRD) can be limited by deficiencies of iron, folate, or vitamin B12, by hyperparathyroidism, or by aluminum intoxication. Folic Acid 121-127 erythropoietin Homo sapiens 26-40 9159297-1 1997 The treatment efficacy of erythropoietin (EPO) in end-stage renal disease (ESRD) can be limited by deficiencies of iron, folate, or vitamin B12, by hyperparathyroidism, or by aluminum intoxication. Folic Acid 121-127 erythropoietin Homo sapiens 42-45 9171313-0 1997 Folic acid supplementation improves erythropoietin response. Folic Acid 0-10 erythropoietin Homo sapiens 36-50 9072885-2 1996 During its treatment by recombinant human erythropoietin (rHuEPO) erythropoiesis is accelerated and this increases demands on the supply of dietary erythropoietic precursors (Fe, pyridoxine, folic acid, vitamin B12). Folic Acid 191-201 erythropoietin Homo sapiens 42-56 8235161-0 1993 [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?]. Folic Acid 36-46 erythropoietin Homo sapiens 89-103 7851040-0 1994 Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment? Folic Acid 3-9 erythropoietin Homo sapiens 90-93 8159473-1 1993 Human recombinant erythropoietin (rHu-Epo) is now extensively used in chronic renal failures; this treatment, resulting in a correction of the severe anemias seen in hemodialysed patients, may in turn lead to a resistance to rHu-Epo therapy by reason of the shortage of erythropoiesis factors, such as iron, vitamin B12 and folates. Folic Acid 324-331 erythropoietin Homo sapiens 18-32 8159473-1 1993 Human recombinant erythropoietin (rHu-Epo) is now extensively used in chronic renal failures; this treatment, resulting in a correction of the severe anemias seen in hemodialysed patients, may in turn lead to a resistance to rHu-Epo therapy by reason of the shortage of erythropoiesis factors, such as iron, vitamin B12 and folates. Folic Acid 324-331 erythropoietin Homo sapiens 38-41 8235161-1 1993 The need for folate supplementation in patients on chronic hemodialysis receiving erythropoietin (EPO) remains to be determined. Folic Acid 13-19 erythropoietin Homo sapiens 82-96 8235161-1 1993 The need for folate supplementation in patients on chronic hemodialysis receiving erythropoietin (EPO) remains to be determined. Folic Acid 13-19 erythropoietin Homo sapiens 98-101 8235161-8 1993 We thus recommend the measurement of serum and red cell folate levels during the first and tenth weeks of the induction phase of EPO treatment. Folic Acid 56-62 erythropoietin Homo sapiens 129-132 1451343-0 1992 Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Folic Acid 3-9 erythropoietin Homo sapiens 64-78 1451343-1 1992 The need for folate supplementation in hemodialysis (HD) patients receiving erythropoietin (EPO) therapy remains unknown. Folic Acid 13-19 erythropoietin Homo sapiens 76-90 19573437-0 2009 [Effects of folic acid and vitamin B12 in the enhanced preterm infants" hematopoiesis by intensified erythropoietin]. Folic Acid 12-22 erythropoietin Homo sapiens 101-115 24294939-0 2014 Modulation of intestinal folate absorption by erythropoietin in vitro. Folic Acid 25-31 erythropoietin Homo sapiens 46-60 24294939-4 2014 The objective of this study was to investigate the effect of EPO on intestinal transport of folate in vitro and to elucidate the possible mechanism(s) involved in this regulation. Folic Acid 92-98 erythropoietin Homo sapiens 61-64 24294939-5 2014 Transport assays of folic acid were performed in Caco-2 monolayers treated with EPO. Folic Acid 20-30 erythropoietin Homo sapiens 80-83 24294939-6 2014 The effect of EPO on the expression of transporters involved in the folate absorption was investigated. Folic Acid 68-74 erythropoietin Homo sapiens 14-17 24294939-8 2014 The absorptive flux (apical to basolateral) of folic acid was enhanced by EPO treatment in a dose-dependent manner, which was companied with the significant up-regulation of reduced folate carrier (RFC) and apical proton coupled folate transporter (PCFT). Folic Acid 47-57 erythropoietin Homo sapiens 74-77 18800231-7 2009 The most predictive model of EPO response for the pediatric cohort had, as the major variables, urea clearance x dialysis duration/total body water (Kt/V), urea reduction ratio (URR), intact parathyroid hormone (iPTH), blood loss, normalized protein catabolic rates (nPCR) and indices of malnutrition and inflammation, whereas adults had iron and folate deficiencies as the dominant variables. Folic Acid 347-353 erythropoietin Homo sapiens 29-32 18800231-10 2009 In summary EPO resistance in the pediatric dialysis cohort was predicted by nutritional deficits, inflammation, poor dialysis, and hyperparathyroidism, while iron and folate deficits were the major determinants in adults. Folic Acid 167-173 erythropoietin Homo sapiens 11-14 31628923-6 2020 CONCLUSION: EPO therapy in conjunction with iron, vitamin E and folic acid, stimulated erythropoiesis and significantly reduced the need for blood transfusion in AOP. Folic Acid 64-74 erythropoietin Homo sapiens 12-15 24294939-8 2014 The absorptive flux (apical to basolateral) of folic acid was enhanced by EPO treatment in a dose-dependent manner, which was companied with the significant up-regulation of reduced folate carrier (RFC) and apical proton coupled folate transporter (PCFT). Folic Acid 182-188 erythropoietin Homo sapiens 74-77 24294939-9 2014 The efflux (basolaterial to apical) of folic acid was enhanced only by the high dose of EPO treatment, which was associated with the significant up-regulation of apical multidrug resistance-associated protein 2 (MRP2). Folic Acid 39-49 erythropoietin Homo sapiens 88-91 24294939-12 2014 As a conclusion, intestinal folate absorption was enhanced by EPO treatment in vitro. Folic Acid 28-34 erythropoietin Homo sapiens 62-65 24294939-13 2014 Our findings provided direct evidence to establish the correlation between EPO and folate homeostasis. Folic Acid 83-89 erythropoietin Homo sapiens 75-78 21697809-7 2011 To minimize the harmful (including fatal) consequences of EPO resistance, surveillance programs must replenish nutrient (for example, iron and folate) stores, minimize oxidative hemolysis, control hyperparathyroidism, avoid catheter infection, and optimize uremic clearance. Folic Acid 143-149 erythropoietin Homo sapiens 58-61 21335214-4 2011 This approach is allowed by the use of recombinant human erythropoietin in association with erythropoiesis-inducing factors such as iron and folic acid. Folic Acid 141-151 erythropoietin Homo sapiens 57-71 18721738-13 2008 CONCLUSIONS: Composite scoring of erythrocyte indices was predictive of the FD diagnosis, as defined by the quantitative response of red blood cell folate, homocysteine, and EPO dose to folate therapeutic intervention. Folic Acid 186-192 erythropoietin Homo sapiens 174-177 16504977-0 2006 High-dose folic acid supplements and responsiveness to rHu-EPO in HD patients. Folic Acid 10-20 erythropoietin Homo sapiens 59-62 16133045-14 2005 Furthermore, the substantial (post-folate) reduction in the EPO requirement validates the need for therapeutic intervention, and therefore the presence of functional FD in the population. Folic Acid 35-41 erythropoietin Homo sapiens 60-63 16818564-3 2006 We hypothesized that combined administration of vitamin B12 and folate with erythropoietin and iron would enhance erythropoietin-induced erythropoiesis. Folic Acid 64-70 erythropoietin Homo sapiens 114-128 16818564-5 2006 RESULTS: During the 4-week observation period, vitamin B12 and folate enhanced erythropoietin-induced erythropoiesis significantly, as indicated by a 10% increase in red blood cell counts, compared with folate alone. Folic Acid 63-69 erythropoietin Homo sapiens 79-93 16818564-5 2006 RESULTS: During the 4-week observation period, vitamin B12 and folate enhanced erythropoietin-induced erythropoiesis significantly, as indicated by a 10% increase in red blood cell counts, compared with folate alone. Folic Acid 203-209 erythropoietin Homo sapiens 79-93 16818564-9 2006 CONCLUSIONS: With the limitation of a slight imbalance in baseline data between the study groups, combined therapy with vitamin B12, folate, erythropoietin, and orally and intravenously administered iron seemed more effective in stimulating erythropoiesis among premature infants, compared with erythropoietin, iron, and low-dose folate alone. Folic Acid 133-139 erythropoietin Homo sapiens 295-309 16818564-9 2006 CONCLUSIONS: With the limitation of a slight imbalance in baseline data between the study groups, combined therapy with vitamin B12, folate, erythropoietin, and orally and intravenously administered iron seemed more effective in stimulating erythropoiesis among premature infants, compared with erythropoietin, iron, and low-dose folate alone. Folic Acid 330-336 erythropoietin Homo sapiens 141-155 16144854-8 2006 The removal of folic acid supplementation resulted in re-occurrence of macrocytosis and in a significantly lower response to rHu-EPO. Folic Acid 15-25 erythropoietin Homo sapiens 129-132